Inhibition of Plasma Kallikrein as a New Therapy for Lung Injury
NCT04848272
·
clinicaltrials.gov ↗
PHASE1
Phase
UNKNOWN
Status
48
Enrollment
OTHER
Sponsor class
Conditions
Lung Injury
Interventions
DRUG:
Lanadelumab
OTHER:
Saline control
Sponsor
St Vincent's Institute of Medical Research